iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/35032336
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;21(10):4171-4175.
doi: 10.1111/jocd.14773. Epub 2022 Feb 10.

Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know

Raquel de Melo Carvalho  1 , Leopoldo Duailibe Nogueira Santos  2 , Paulo Müller Ramos  3 , Carla Jorge Machado  4 , Patricia Acioly  5 , Simone Carolina Frattini  6 , Carlos Baptista Barcaui  5 , André Luiz Vairo Donda  5 , Daniel Fernandes Melo  5
Affiliations
Review

Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know

Raquel de Melo Carvalho et al. J Cosmet Dermatol. 2022 Oct.

Abstract

Female pattern hair loss (FPHL) is the most common form of alopecia in women. FPHL may compromise body image and strongly affect self-esteem, negatively impacting quality of life. Currently, the only Food and Drug Administration (FDA) approved drug for its treatment is topical minoxidil, with a variable response rate. Recently, a few studies in FPHL have pointed out bicalutamide as an emergent selective androgen receptor antagonist with a favorable safety and tolerability profile. This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It does not cross the blood-brain barrier, and it has little effect on serum luteinizing hormone. Additionally, bicalutamide was found to be effective on women presenting with other features of hyperandrogenism such as seborrhea, acne, and hirsutism with mild and well-tolerated adverse effects. Despite the high prevalence and psychosocial impairment, FPHL treatment remains challenging. Therefore, although future prospective, comparative, randomized clinical trials are essential to establish the ideal dose and efficacy of the drug, oral bicalutamide appears to be a promising option to expand the arsenal of FPHL treatment.

Keywords: alopecia; androgenetic alopecia; antiandrogens; bicalutamide; female pattern hair loss.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Ramos PM, Miot HA. Female Pattern Hair Loss: a clinical and pathophysiological review. An Bras Dermatol. 2015;90(4):529-543. 10.1590/abd1806-4841.20153370
    1. Bhat YJ, Saqib NU, Latif I, Hassan I. Female Pattern Hair Loss-An Update. Indian Dermatol Online J. 2020;11(4):493-501. 10.4103/idoj.IDOJ_334_19
    1. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91-95.
    1. Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R. Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients. J Am Acad Dermatol. 2020;83(5):1478-1479.
    1. Ricci F, Buzzatti G, Rubagotti A, Boccardo F. Safety of antiandrogen therapy for treating prostate cancer. Expert Opin Drug Saf. 2014;13(11):1483-1499.

LinkOut - more resources